Lintitript

Lintitript (SR 27897) is a highly potent, selective, orally active, competitive and non-peptide cholecystokinin (CCK1) receptor antagonist with an EC50 of 6 nM and a Ki of 0.2 nM. Lintitript displays > 33-fold selectivity more selective for CCK1 than CCK2 receptors (EC50 value of 200 nM) . Lintitript increases plasma concentration of leptin and food intake as well as plasma concentration of insulin[1][2][3].

Product Specifications

CAS Number

[136381-85-6]

Product Name Alternative

SR 27897

UNSPSC

12352005

Hazard Statement

H301, H318

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lintitript.html

Purity

99.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CN1C(C(NC2=NC(C3=CC=CC=C3Cl)=CS2)=O)=CC4=C1C=CC=C4

Molecular Formula

C20H14ClN3O3S

Molecular Weight

411.86

Precautions

H301, H318

References & Citations

[1]Gully D, et al. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol. 1993 Feb 23;232 (1) :13-9.|[2]Gouldson P, et al. Contrasting roles of leu (356) in the human CCK (1) receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur J Pharmacol. 1999 Nov 3;383 (3) :339-46.|[3]Cano V, et al. Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. Br J Pharmacol. 2003 Oct;140 (4) :647-52.